A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy.Biomedicines · 2021
   Review
2. Thanatogenomic Investigation of the Hydroxymethylome and Mitochondrial Genome of Cadaveric Cardiomyocytes: Proposal for a Proof-of-Concept Study.JMIR research protocols · 2020
   Article

Corrections and comments

• Commented on by
  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.2017
• Comment on
  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as